Philip Binns Biography and Net Worth

Philip (Phil) Binns joined Agilent as Vice President and General Manager for the Spectroscopy Division following the acquisition of Varian, Inc. in 2010. In 2015, the Vacuum products team became part of the expanded division now known as the Spectroscopy and Vacuum Solutions Division.

Phil joined Varian’s Spectroscopy Group in 1994, after beginning his career in the mining and minerals industry. He has held management positions in product marketing and development, and sales and operations. In 2004, he was appointed General Manager of Varian’s field operations in the Pacific Rim.

Outside of Agilent, Phil has held a number of positions mentoring startups in the technology space and is a current board member of a medical bionics research institute and an early-stage company focused on treatment for epilepsy. Phil’s background is in Applied Science along with post-graduate qualifications in Marketing and an MBA from The University of Melbourne.

Phil and his wife live in Melbourne, Australia. Together, they have three adult children.

In his down time, Phil enjoys spending time with his family, traveling, participating in active sports such as skiing and hiking and following Australian Rules football.

What is Philip Binns' net worth?: The estimated net worth of Philip Binns is at least $1.38 million as of March 25th, 2024. Mr. Binns owns 9,997 shares of Agilent Technologies stock worth more than $1,376,487 as of April 26th. This net worth approximation does not reflect any other assets that Mr. Binns may own. Learn More about Philip Binns' net worth.
How do I contact Philip Binns?: The corporate mailing address for Mr. Binns and other Agilent Technologies executives is 5301 STEVENS CREEK BLVD, SANTA CLARA CA, 95051. Agilent Technologies can also be reached via phone at (800) 227-9770 and via email at [email protected]. Learn More on Philip Binns' contact information.
Has Philip Binns been buying or selling shares of Agilent Technologies?: Philip Binns has not been actively trading shares of Agilent Technologies over the course of the past ninety days. Most recently, Philip Binns sold 2,827 shares of the business's stock in a transaction on Monday, March 25th. The shares were sold at an average price of $147.54, for a transaction totalling $417,095.58. Following the completion of the sale, the senior vice president now directly owns 9,997 shares of the company's stock, valued at $1,474,957.38. Learn More on Philip Binns' trading history.
Who are Agilent Technologies' active insiders?: Agilent Technologies' insider roster includes Henrik Ancher-Jensen (SVP), Philip Binns (SVP), Heidi Fields (Director), Rodney Gonsalves (VP), Dominique Grau (SVP), Boon Koh (Director), Padraig Mcdonnell (VP), Michael Mcmullen (CEO), Samraat Raha (VP), Michael Tang (SVP), and Jacob Thaysen (VP). Learn More on Agilent Technologies' active insiders.
Are insiders buying or selling shares of Agilent Technologies?: In the last twelve months, Agilent Technologies insiders bought shares 1 times. They purchased a total of 3 shares worth more than $333.27. In the last twelve months, insiders at the medical research company sold shares 11 times. They sold a total of 161,983 shares worth more than $22,489,381.86. The most recent insider tranaction occured on March, 25th when SVP Philip Binns sold 2,827 shares worth more than $417,095.58. Learn More about insider trades at Agilent Technologies.
Information on this page was last updated on 3/25/2024.

Philip Binns Insider Trading History at Agilent Technologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/25/2024	Sell	2,827	$147.54	$417,095.58	9,997
12/27/2023	Sell	2,880	$139.78	$402,566.40	12,824

Philip Binns Buying and Selling Activity at Agilent Technologies

Agilent Technologies Company Overview

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Today's Range

Now: $137.69

$135.00

$138.36

50 Day Range

MA: $141.59

$131.49

$149.36

2 Week Range

Now: $137.69

$96.80

$151.58

Volume

754,945 shs

Average Volume

1,562,308 shs

Market Capitalization

$40.35 billion

P/E Ratio

32.78

Dividend Yield

0.68%

Beta

1.11

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report